JPWO2022186349A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022186349A5 JPWO2022186349A5 JP2022539639A JP2022539639A JPWO2022186349A5 JP WO2022186349 A5 JPWO2022186349 A5 JP WO2022186349A5 JP 2022539639 A JP2022539639 A JP 2022539639A JP 2022539639 A JP2022539639 A JP 2022539639A JP WO2022186349 A5 JPWO2022186349 A5 JP WO2022186349A5
- Authority
- JP
- Japan
- Prior art keywords
- fibroblasts
- pharmaceutical composition
- adm
- hhex
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000002950 fibroblast Anatomy 0.000 claims 35
- 239000008194 pharmaceutical composition Substances 0.000 claims 24
- 230000014509 gene expression Effects 0.000 claims 21
- 210000004027 cell Anatomy 0.000 claims 17
- 102100035961 Hematopoietically-expressed homeobox protein HHEX Human genes 0.000 claims 9
- 101001021503 Homo sapiens Hematopoietically-expressed homeobox protein HHEX Proteins 0.000 claims 9
- 210000004072 lung Anatomy 0.000 claims 5
- 101150054360 ADM gene Proteins 0.000 claims 3
- 208000019693 Lung disease Diseases 0.000 claims 2
- 102000009520 Vascular Endothelial Growth Factor C Human genes 0.000 claims 2
- 108010073923 Vascular Endothelial Growth Factor C Proteins 0.000 claims 2
- 230000001771 impaired effect Effects 0.000 claims 2
- 239000007972 injectable composition Substances 0.000 claims 2
- 230000035168 lymphangiogenesis Effects 0.000 claims 2
- 206010016654 Fibrosis Diseases 0.000 claims 1
- 101150097704 HHEX gene Proteins 0.000 claims 1
- 208000029523 Interstitial Lung disease Diseases 0.000 claims 1
- 206010030113 Oedema Diseases 0.000 claims 1
- 230000003213 activating effect Effects 0.000 claims 1
- 210000003969 blast cell Anatomy 0.000 claims 1
- 230000003247 decreasing effect Effects 0.000 claims 1
- 239000000835 fiber Substances 0.000 claims 1
- 230000004761 fibrosis Effects 0.000 claims 1
- 239000012530 fluid Substances 0.000 claims 1
- 230000013632 homeostatic process Effects 0.000 claims 1
- 230000037451 immune surveillance Effects 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 1
- 229940088594 vitamin Drugs 0.000 claims 1
- 229930003231 vitamin Natural products 0.000 claims 1
- 235000013343 vitamin Nutrition 0.000 claims 1
- 239000011782 vitamin Substances 0.000 claims 1
- 150000003722 vitamin derivatives Chemical class 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023020860A JP2023058660A (ja) | 2021-03-04 | 2023-02-14 | リンパ管新生促進因子発現線維芽細胞及びそれを含む医薬組成物 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021034018 | 2021-03-04 | ||
| JP2021034018 | 2021-03-04 | ||
| JP2021034016 | 2021-03-04 | ||
| JP2021034016 | 2021-03-04 | ||
| PCT/JP2022/009205 WO2022186349A1 (ja) | 2021-03-04 | 2022-03-03 | リンパ管新生促進因子発現線維芽細胞及びそれを含む医薬組成物 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023020860A Division JP2023058660A (ja) | 2021-03-04 | 2023-02-14 | リンパ管新生促進因子発現線維芽細胞及びそれを含む医薬組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JPWO2022186349A1 JPWO2022186349A1 (https=) | 2022-09-09 |
| JPWO2022186349A5 true JPWO2022186349A5 (https=) | 2023-02-01 |
| JP7233147B2 JP7233147B2 (ja) | 2023-03-06 |
Family
ID=83155368
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022539639A Active JP7233147B2 (ja) | 2021-03-04 | 2022-03-03 | リンパ管新生促進因子発現線維芽細胞及びそれを含む医薬組成物 |
| JP2023020860A Withdrawn JP2023058660A (ja) | 2021-03-04 | 2023-02-14 | リンパ管新生促進因子発現線維芽細胞及びそれを含む医薬組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023020860A Withdrawn JP2023058660A (ja) | 2021-03-04 | 2023-02-14 | リンパ管新生促進因子発現線維芽細胞及びそれを含む医薬組成物 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20240148795A1 (https=) |
| EP (1) | EP4302771A4 (https=) |
| JP (2) | JP7233147B2 (https=) |
| KR (1) | KR20230154177A (https=) |
| AU (1) | AU2022231584A1 (https=) |
| CA (1) | CA3211113A1 (https=) |
| IL (1) | IL305069A (https=) |
| WO (1) | WO2022186349A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20240316113A1 (en) * | 2021-09-08 | 2024-09-26 | Metcela Inc. | Fibroblast-containing pharmaceutical composition for treating kidney disease |
| JP2025515887A (ja) | 2022-11-11 | 2025-05-20 | エルジー エナジー ソリューション リミテッド | 負極活物質、これを含む負極、これを含む二次電池、および負極活物質の製造方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102407387B1 (ko) * | 2017-02-24 | 2022-06-10 | 가부시키가이샤 메토세라 | 섬유아세포를 포함하고, 심장 질환들의 치료를 위하여 사용될 수 있는 주사용 조성물, 및 치료 용도를 위하여 섬유아세포를 생산하는 방법 |
| EP3845635A4 (en) | 2018-08-29 | 2022-06-15 | Metcela Inc. | PROCEDURE FOR PREPARING FIBROBLAST AND G-CSF-POSITIVE FIBROBLAST MASS |
| US20240316113A1 (en) * | 2021-09-08 | 2024-09-26 | Metcela Inc. | Fibroblast-containing pharmaceutical composition for treating kidney disease |
-
2022
- 2022-03-03 CA CA3211113A patent/CA3211113A1/en active Pending
- 2022-03-03 AU AU2022231584A patent/AU2022231584A1/en active Pending
- 2022-03-03 KR KR1020237027718A patent/KR20230154177A/ko active Pending
- 2022-03-03 IL IL305069A patent/IL305069A/en unknown
- 2022-03-03 WO PCT/JP2022/009205 patent/WO2022186349A1/ja not_active Ceased
- 2022-03-03 EP EP22763401.1A patent/EP4302771A4/en active Pending
- 2022-03-03 JP JP2022539639A patent/JP7233147B2/ja active Active
- 2022-03-03 US US18/548,803 patent/US20240148795A1/en active Pending
-
2023
- 2023-02-14 JP JP2023020860A patent/JP2023058660A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Zhou et al. | The polysaccharides from the fruits of Lycium barbarum L. confer anti-diabetic effect by regulating gut microbiota and intestinal barrier | |
| JPWO2022186349A5 (https=) | ||
| Awada et al. | A single injection of protein-loaded coacervate-gel significantly improves cardiac function post infarction | |
| JP2023058660A5 (https=) | ||
| EP1959988B1 (en) | Use of bovine lactoferrin for treating destructive inflammation of mucous membrane | |
| Wang et al. | Dendrobium fimbriatum polysaccharide ameliorates DSS-induced intestinal mucosal injury by IL-22-regulated intestinal stem cell regeneration | |
| Zhou et al. | Progress in cytokine research for ARDS: A comprehensive review | |
| Sahl Jr et al. | Cutaneous scars: part I. | |
| Saburi et al. | The use of mesenchymal stem cells in the process of treatment and tissue regeneration after recovery in patients with Covid-19 | |
| Gan et al. | Commensal microbe regulation of skin cells in disease | |
| Menni et al. | Looking for the ideal probiotic healing regime | |
| Safdarpour et al. | Encapsulated saponin by ferritin nanoparticles attenuates the murine pneumococcal pneumonia | |
| Rial et al. | Experimental combination therapy using low doses of benznidazole and allopurinol in mouse models of Trypanosoma cruzi chronic infection | |
| Xiong et al. | Endothelial progenitor-cell-derived exosomes induced by astragaloside IV accelerate type I diabetic-wound healing via the PI3K/AKT/mTOR pathway in rats | |
| Li et al. | Microglia in Post‐Traumatic Brain Injury (TBI) Cognitive Impairment: From Pathological Changes to Therapeutic Approaches | |
| Liu et al. | A novel function of benzoic acid to enhance intestinal barrier defense against PEDV infection in Piglets | |
| Huang et al. | Crosstalk between gut microbiota and renal ischemia/reperfusion injury | |
| Palumbo et al. | Topical application of a hyaluronic acid-based hydrogel integrated with secretome of human mesenchymal stromal cells for diabetic ulcer repair | |
| Huang et al. | Arabinoxylan from barley bran alleviates ulcerative colitis in mice through enhancement of mucosal barrier function and modulation of gut microbiota | |
| Gai et al. | Antiproliferative effect of echinacoside on rat pulmonary artery smooth muscle cells under hypoxia | |
| Ha et al. | Enhancement of gastric ulcer healing and angiogenesis by hepatocyte growth factor gene mediated by attenuated salmonella in rats | |
| CN118873667A (zh) | Lat1抑制剂在制备治疗动脉粥样硬化的药物中的应用 | |
| US20220072031A1 (en) | Treatment of viral infection | |
| Kang et al. | A new Synbiotic supplementation ameliorates ulcerative colitis via modulating microbial homeostasis, protecting intestinal barrier integrity, and maintaining immunity homeostasis in mice | |
| WO2023178338A3 (en) | Methods and compositions for treating tmem43 related cardiomyopathy with a viral vector |